You are here

Akcea

Nearly 70% of Akcea's workforce is on the chopping block as Ionis executes major restructuring

Endpoints

Tue, 04/6/21 - 11:04 pm

Ionis, Akcea boosted by a positive PhII for their Novartis castoff cardio drug — and they plan to push ahead into pivotals

Endpoints

Wed, 01/22/20 - 11:00 am

AKCEA-APOCIII-LRx

Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev news

EP Vantage

Sun, 01/5/20 - 07:11 pm

Multiple Myeloma

Ionis Pharmaceuticals

AKCEA-ANGPTL3-Lrx

Novartis elects to keep one heart drug, discard the other from option deal with Akcea, Ionis

Endpoints

Thu, 12/19/19 - 12:51 pm

ACEKA-APOCIII-L

Akcea, Fresh Off C-Suite Shakeup, Dishes Heart Drug to Pfizer for $250M

Xconomy

Mon, 10/7/19 - 11:18 am

Ionis Pharmaceuticals

AKCEA-ANGPTL3-Lrx

The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Yahoo/Benzinga

Sun, 07/28/19 - 11:48 pm

Leap Therapeutics

Cidara Therapeutics

Spark Therapeutics

clinical trials

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

Xconomy

Mon, 05/6/19 - 10:54 am

AbbVie, Akcea benefit from latest CHMP recommendations

Biopharma Dive

Sun, 03/3/19 - 07:12 pm

Early November Brings More Quarterly Reports

BioSpace

Sun, 11/4/18 - 02:38 pm

FDA clears rare disease therapy from Akcea, Ionis

Biopharma Dive

Fri, 10/5/18 - 09:38 pm

Ionis Pharmaceuticals

hATTR amyloidosis

FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead

CP Wire

Fri, 05/4/18 - 09:58 am

hereditary ATTR amyloidosis

Ionis Sends Nerve Drug to Spinout Akcea as Battle with Alnylam Looms

Xconomy

Thu, 03/15/18 - 11:09 am

Ionis Pharmaceuticals

transthyretin amyloidosis

Ionis-spinout Akcea prices IPO below expected range

Drug Delivery Business News

Sat, 07/15/17 - 11:23 am

Akcea now shooting for $200M-plus as a new lineup of biotech IPOs prep for a launch

Endpoints

Tue, 06/20/17 - 09:51 am